Shares of small-cap oncology biotech Puma Biotechnology Inc (NASDAQ: PBYI) are sinking to their lowest level since November following the release of its first-quarter results.
Nerlynx Numbers Disappoint
While Puma beat consensus earnings and revenue estimates, it appears to be an update on Nerlynx, its first commercial product, that's sending the stock into freefall.
Puma said its product revenues stem entirely from sales of the treatment, which has been approved for treating early stage, previously treated HER 2+ breast cancer.
The FDA approved the once-daily oral tablet in July 2017.
A Nerlynx sales miss in the third quarter of 2018 sent Puma's shares down by about 50 percent Nov. 2.
Nerlynx revenues, though increasing 27 percent year-over-year, represented a 25-percent drop from the $61.1 million reported for the fourth quarter of 2018.
"Puma experienced lower than expected net product revenue in the first quarter of 2019," Puma CEO Alan Auerbach said in a statement.
The decline was attributed to an increase in expenses charged against gross revenue and an increase in patients discontinuing Nerlynx treatment.
A string of downgrades followed the earnings announcement: Citigroup downgraded the stock from Buy to Neutral, while Cantor Fitzgerald downgraded the stock from Overweight to Neutral and reduced the price target to $20.
Puma shares were down 36.86 percent at $18.95 at the time of publication Friday.
The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales
Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study
See more from Benzinga
- The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales
- The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut
- The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.